Approval · Notice of Compliance 25970 · 2021
KYPROLIS: Notice of Compliance 25970
Issued June 2, 2021
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 25970
- Date
- June 2, 2021
- Company
- Amgen Canada IncMississauga, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Change in the drug product manufacturing process
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| KYPROLIS | Not yet assigned | — |
Medicinal ingredients
- CARFILZOMIB 60 MG per VIAL
- CARFILZOMIB 30 MG per VIAL
- CARFILZOMIB 10 MG per VIAL